Lock in a year of Digiday+ for 35% less.
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Premier League gambling ban gives brand sponsors an open goal, but CMOs must still prove value
An exodus of betting brands from the Premier League means there’s a chance for marketers to bag cut-price soccer partnerships. But proving the worth of that investment is another concern.
In Graphic Detail: Why OpenAI’s ad business is still a work in progress
As OpenAI is reportedly gearing up to go public as early as September, Digiday has charted the promise, and early tensions behind its ad business.
The AI paradox: Marketers trust AI to buy media, not build brands
Some executives are wary of AI-generated creative ideas while using automated tools to brainstorm campaigns.